EMERYVILLE, Calif., April 21,
2022 /PRNewswire/ -- Dynavax Technologies Corporation
(Nasdaq: DVAX), a commercial stage biopharmaceutical company
focused on developing and commercializing innovative vaccines, will
report first quarter 2022 financial results on Thursday, May 5, 2022, after the U.S. financial
markets close.
Dynavax will host a conference call and live audio webcast on
Thursday, May 5, 2022 at 4:30 p.m. (ET)/1:30 p.m.
(PT).
The live audio webcast may be accessed through the "Events &
Presentations" page on the "Investors" section of the Company's
website at https://investors.dynavax.com/events-presentations.
Alternatively, participants may dial (866) 420-4066 or (409)
217-8237 and refer to conference ID 4282730. A replay of the
webcast will be available for 30 days following the live event.
About Dynavax
Dynavax is a commercial stage biopharmaceutical company
developing and commercializing innovative vaccines to help protect
the world against infectious diseases. The Company has two
commercial products, HEPLISAV-B® [Hepatitis B Vaccine
(Recombinant), Adjuvanted], which is approved in the U.S. and the
European Union for prevention of infection caused by all known
subtypes of hepatitis B virus in adults age 18 years and older, and
CpG 1018 adjuvant, currently used in multiple adjuvanted COVID-19
vaccines. Dynavax is advancing CpG 1018 adjuvant as a premier
vaccine adjuvant through global research collaborations and
partnerships. Current collaborations are focused on adjuvanted
vaccines for COVID-19, plague, shingles, Tdap, seasonal influenza
and universal influenza. For more information about our marketed
products and development pipeline, visit www.dynavax.com and
follow Dynavax on LinkedIn.
Contacts:
Nicole Arndt,
Senior Manager, Investor Relations
narndt@dynavax.com
510-665-7264
Derek Cole, President
Investor Relations Advisory Solutions
derek.cole@IRadvisory.com
View original
content:https://www.prnewswire.com/news-releases/dynavax-to-report-first-quarter-2022-financial-results-and-host-conference-call-on-may-5-2022-301526392.html
SOURCE Dynavax Technologies